Publication & Citation Trends
Most Cited Works
Publications
79 total
Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F PDF
Cited by 484
OpenAlex
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance PDF
Cited by 277
OpenAlex
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity PDF
Cited by 162
OpenAlex
Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting PDF
Cited by 96
OpenAlex
A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition
Cited by 80
OpenAlex
Identification of Cys255 in HIF‐1α as a novel site for development of covalent inhibitors of HIF‐1α/ARNT PasB domain protein–protein interaction PDF
Cited by 79
OpenAlex
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies PDF
Cited by 132
OpenAlex
Research Topics
Monoclonal and Polyclonal Antibodies Research
(20)
Cell Adhesion Molecules Research
(15)
HER2/EGFR in Cancer Research
(13)
NF-κB Signaling Pathways
(7)
Cancer-related Molecular Pathways
(6)
Frequent Co-Authors
Affiliations
University of Veterinary Medicine Vienna
Pfizer (United States)
University of California, San Diego
Retriev Technologies (United States)
Pfizer (Italy)